- Aurobindo Pharma's subsidiary facility was inspected by the USFDA from August 24-28
- The inspection covered Unit-VI, an API manufacturing plant in Anakapalli district, Andhra Pradesh
- The USFDA issued three procedural observations after the inspection at the subsidiary unit
Aurobindo Pharma Ltd on Friday said the US health regulator has issued three observations after inspecting a facility of its subsidiary in Andhra Pradesh.
The United States Food and Drug Administration (USFDA) inspected Unit-VI, an API manufacturing facility of Apitoria Pharma Pvt Ltd, a wholly-owned subsidiary of the company, at E-Bonangi Village in Anakapalli district, Andhra Pradesh, from August 24 to 28, Aurobindo Pharma said in a regulatory filing.
"We wish to inform that the inspection concluded with three observations, which are procedural in nature, and we will respond to the USFDA within the stipulated timeline," the company said in the filing.
The company further asserted that it is committed to maintaining robust quality and compliance standards across its manufacturing facilities.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
